This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Quest Diagnostics Acquires UMass Memorial Medical Center's Clinical And Anatomic Pathology Outreach Laboratory Businesses

Stocks in this article: DGX

MADISON, N.J. and WORCESTER, Mass., Jan. 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the Worcester-based clinical outreach laboratory business of UMass Memorial Medical Center, a member of UMass Memorial Health Care, the largest health care system in Central New England. Separately, the company also announced today that it has acquired UMass Memorial's anatomic pathology outreach laboratory business, also based in Worcester. Financial terms were not disclosed.

In addition, Quest Diagnostics announced that it has finalized a lease agreement for 200,000 square feet in a facility in Marlborough, Mass., in which it will build a state-of-the-art clinical laboratory. The testing services of the acquired UMass Memorial laboratory businesses as well as Quest Diagnostics' existing full-service clinical laboratory in Cambridge, Mass. and its Athena Diagnostics specialty neurology testing subsidiary in Worcester will transition to the new facility when it becomes fully operational, which is expected to take 18 to 24 months. The facility will be developed based on best practices from Quest Diagnostics' network of laboratories in the United States, and eventually will employ as many as 1,200 medical, administrative and logistics staff.

The acquisitions of the UMass Memorial businesses will add approximately 50 new patient service centers to the company's current roster of about 75 in the state while also extending the range of diagnostic information services Quest Diagnostics provides to physicians and patients in New England. As part of the transactions, academic faculty and other clinical and laboratory experts from UMass Memorial and its academic partner University of Massachusetts Medical School will provide physician pathology and other clinical services to Quest Diagnostics.

Once the facility in Marlborough is fully operational, UMass Memorial has the option to invest in a minority financial stake in Quest Diagnostics' business in Massachusetts.

"Our UMass Memorial relationship and planned 'lab of the future' represent a new model for delivering diagnostic information services for our nation's increasingly cost-pressured healthcare system," said Steve Rusckowski, president and CEO, Quest Diagnostics. "We look forward to bringing together the academic expertise of UMass Memorial with the advanced testing, scale and operational excellence of Quest Diagnostics' independent lab business. Over time, this powerful combination will deliver a broader range of clinically important services for physicians and patients, but at costs lower than many hospital outreach labs can match." 

"We are also excited to deepen our long-standing commitment to Massachusetts and New England with our selection of Marlborough as the location for our future lab," said Mr. Rusckowski. "Once operational, the facility will be a vital asset in our network of laboratories in the United States and a source of quality healthcare jobs in the state. It will also provide the basis for us to continue to grow in New England and build shareholder value."

"Given the high cost of healthcare and reimbursement pressures in the U.S., it is incumbent upon healthcare leaders to develop creative solutions for delivering high-quality, more affordable patient-centered care," said John O'Brien, president and CEO, UMass Memorial Health Care. "This transaction with Quest Diagnostics will allow us to focus on our core hospital services, while ensuring that our physicians and patients receive exceptional diagnostic services from the industry leader."

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,655.04 +298.17 1.72%
S&P 500 2,045.56 +32.67 1.62%
NASDAQ 4,725.8240 +81.5120 1.76%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs